Invenomic Capital Management LP Increases Stake in DENTSPLY SIRONA Inc. $XRAY

Invenomic Capital Management LP lifted its holdings in shares of DENTSPLY SIRONA Inc. (NASDAQ:XRAY) by 48.7% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,351,199 shares of the medical instruments supplier’s stock after purchasing an additional 1,425,637 shares during the period. DENTSPLY SIRONA accounts for about 2.7% of Invenomic Capital Management LP’s portfolio, making the stock its 2nd biggest position. Invenomic Capital Management LP owned 2.18% of DENTSPLY SIRONA worth $55,217,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in shares of DENTSPLY SIRONA during the 1st quarter worth approximately $26,000. Huntington National Bank boosted its stake in DENTSPLY SIRONA by 292.9% during the third quarter. Huntington National Bank now owns 2,786 shares of the medical instruments supplier’s stock worth $35,000 after acquiring an additional 2,077 shares in the last quarter. True Wealth Design LLC boosted its stake in DENTSPLY SIRONA by 49.7% during the third quarter. True Wealth Design LLC now owns 3,557 shares of the medical instruments supplier’s stock worth $45,000 after acquiring an additional 1,181 shares in the last quarter. Central Pacific Bank Trust Division grew its holdings in DENTSPLY SIRONA by 100.0% in the third quarter. Central Pacific Bank Trust Division now owns 4,000 shares of the medical instruments supplier’s stock worth $51,000 after purchasing an additional 2,000 shares during the period. Finally, Versant Capital Management Inc increased its stake in DENTSPLY SIRONA by 878.6% in the third quarter. Versant Capital Management Inc now owns 4,883 shares of the medical instruments supplier’s stock valued at $62,000 after purchasing an additional 4,384 shares in the last quarter. 95.70% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other DENTSPLY SIRONA news, Director Gregory T. Lucier acquired 15,000 shares of the business’s stock in a transaction dated Monday, March 9th. The stock was bought at an average price of $12.45 per share, with a total value of $186,750.00. Following the purchase, the director owned 65,000 shares of the company’s stock, valued at approximately $809,250. This trade represents a 30.00% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director James D. Forbes bought 5,000 shares of DENTSPLY SIRONA stock in a transaction that occurred on Monday, March 9th. The shares were acquired at an average cost of $12.48 per share, for a total transaction of $62,400.00. Following the acquisition, the director owned 10,000 shares in the company, valued at $124,800. The trade was a 100.00% increase in their position. The SEC filing for this purchase provides additional information. Over the last 90 days, insiders bought 70,000 shares of company stock valued at $956,437. Company insiders own 0.52% of the company’s stock.

DENTSPLY SIRONA Stock Performance

NASDAQ XRAY opened at $11.54 on Monday. The company has a market capitalization of $2.31 billion, a P/E ratio of -3.85, a P/E/G ratio of 1.35 and a beta of 0.97. The company has a debt-to-equity ratio of 1.50, a quick ratio of 1.03 and a current ratio of 1.51. DENTSPLY SIRONA Inc. has a 52-week low of $9.85 and a 52-week high of $17.18. The company has a fifty day moving average of $12.73 and a 200-day moving average of $12.38.

DENTSPLY SIRONA (NASDAQ:XRAY) last issued its quarterly earnings results on Thursday, February 26th. The medical instruments supplier reported $0.27 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.28 by ($0.01). The firm had revenue of $961.00 million for the quarter, compared to the consensus estimate of $926.40 million. DENTSPLY SIRONA had a positive return on equity of 18.85% and a negative net margin of 16.25%.The company’s revenue for the quarter was up 6.2% on a year-over-year basis. During the same period last year, the firm earned $0.26 EPS. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. As a group, equities research analysts predict that DENTSPLY SIRONA Inc. will post 1.84 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have issued reports on XRAY. Mizuho lifted their price objective on shares of DENTSPLY SIRONA from $14.00 to $16.00 and gave the stock a “neutral” rating in a report on Monday, March 2nd. Barclays assumed coverage on DENTSPLY SIRONA in a research note on Monday, December 8th. They issued an “underweight” rating and a $12.00 target price on the stock. Bank of America raised DENTSPLY SIRONA from a “neutral” rating to a “buy” rating and increased their price target for the company from $13.00 to $17.00 in a research report on Thursday, February 19th. Robert W. Baird lifted their price target on DENTSPLY SIRONA from $12.00 to $14.00 and gave the stock a “neutral” rating in a report on Friday, February 27th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of DENTSPLY SIRONA in a research note on Wednesday, January 21st. Three equities research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $14.42.

About DENTSPLY SIRONA

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.